Moderna's ba.4/ba.5 targeting bivalent booster, mrna-1273.222, meets primary endpoint of superiority against omicron variants compared to booster dose of mrna-1273 in phase 2/3 clinical trial
In a phase 2/3 trial in over 500 adults, mrna-1273.222, induced significantly higher neutralizing antibody titers against ba.4/ba.5 compared to a booster dose of mrna-1273 results build upon data recently published in the new england journal of medicine that confirmed superiority of the company's ba.1 bivalent vaccine, mrna-1273.214, neutralizing titers against multiple omicron variants compared to a booster dose of mrna-1273 both of the company's updated bivalent boosters (mrna-1273.214 and mrna-1273.222) showed neutralizing titers against bq.1.1, an emerging threat globally, in an exploratory analysis safety and tolerability of mrna-1273.214 and mrna-1273.222 were similar to a booster dose of mrna-1273 and adverse events were generally lower than the second dose of the primary series cambridge, ma / accesswire / november 14, 2022 / moderna, inc., (nasdaq:mrna) a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, today announced that both of moderna's bivalent omicron-targeting booster candidates (mrna-1273.214 and mrna-1273.222) trigger a superior antibody response compared to a booster dose of mrna-1273, the company's prototype vaccine, against omicron (ba.4/ba.5) in phase 2/3 clinical trials. both bivalent vaccines also met non-inferiority immunogenicity criteria to the original strain.
MRNA Ratings Summary
MRNA Quant Ranking
You've reached your free article limit.
Want To Read More Articles?
See what it all means for your stocks with premium tools
Stockprices is a weekly video covering what moved markets
this week, featuring a panel of Stockprices editors. It is published by the
close of trading on Fridays. Hosted by Nathaniel E. Baker, contributing editor,
and featuring: Aaron Task, VP Contributor Content and co-host Stockprices's Alpha
Trader podcast; Brad Olesen, VP News; Steve Alpher, Managing Editor News, co-host
Alpha Trader.
Unsubscribe From All
You successfully activated
“Only Essentials”
Confirm Upgrade
Your subscription will be moved to the annual plan. Service will automatically renew unless cancelled. No Refunds. Click upgrade to confirm.
Stockprices uses Plaid to connect you account
Connect effortlessly
Plaid lets you securely connect your financial accounts in seconds
Your data belongs to you
Plaid doesn't sell personal info, and will only use it with your permission